头孢洛扎/他唑巴坦与头孢他啶/阿维巴坦早期治疗非COVID-19耐多药铜绿假单胞菌肺炎患者的比较评价
两组死亡率、指数培养后住院时长和费用无显著差异;头孢洛扎/他唑巴坦组复发性耐多药铜绿假单胞菌肺炎和60天肺炎相关再入院更低、出院回家更多、调整后抗生素费用更低,DOOR分析更倾向有利结局。作者认为早期头孢洛扎/他唑巴坦可能带来一些临床和费用获益,需进一步大规模研究。
要点
- 两组死亡率、指数培养后住院时长和费用无显著差异。
- 头孢洛扎/他唑巴坦组复发性耐多药铜绿假单胞菌肺炎7.9% vs 头孢他啶/阿维巴坦组18.0%(P=0.03)。
- 头孢洛扎/他唑巴坦组60天肺炎相关再入院11.1% vs 28.5%,出院回家25.8% vs 9.8%(均P=0.03)。
核心结论
- 早期使用头孢洛扎/他唑巴坦较头孢他啶/阿维巴坦可能为耐多药铜绿假单胞菌肺炎患者带来一些临床和费用获益。
- 作者认为需进一步大规模研究以全面了解这些治疗用于耐多药铜绿假单胞菌肺炎的结局。
研究设计与样本
- 患者需在指数培养3天内接受头孢洛扎/他唑巴坦或头孢他啶/阿维巴坦且用药≥2天,最终样本197例(头孢洛扎/他唑巴坦117例,头孢他啶/阿维巴坦80例)。
主要发现
- 两组死亡率和指数培养后住院时长及费用无显著差异。
- 多变量分析中,头孢洛扎/他唑巴坦组较头孢他啶/阿维巴坦组复发性耐多药铜绿假单胞菌肺炎更低(7.9% vs 18.0%,P=0.03)。
- 头孢洛扎/他唑巴坦组较头孢他啶/阿维巴坦组60天肺炎相关再入院更低(11.1% vs 28.5%,P=0.03),出院回家更多(25.8% vs 9.8%,P=0.03)。
- 头孢洛扎/他唑巴坦组较头孢他啶/阿维巴坦组调整后中位总抗生素费用更低(5052美元 vs 8099美元,P=0.003),调整后中位对照抗生素费用更低(3938美元 vs 6441美元,P=0.005)。
- DOOR分析中,头孢洛扎/他唑巴坦治疗患者较头孢他啶/阿维巴坦治疗患者更可能获得更有利结局(DOOR概率59.6%,95%CI 52.5%—66.8%)。
临床怎么用
- 作者认为早期头孢洛扎/他唑巴坦较头孢他啶/阿维巴坦可能为耐多药铜绿假单胞菌肺炎患者带来一些临床和费用获益。
- 作者认为需进一步大规模研究以全面了解这些治疗用于耐多药铜绿假单胞菌肺炎的结局。
局限性
- 作者认为需进一步大规模研究以全面了解这些治疗用于耐多药铜绿假单胞菌肺炎的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ceftolozane/tazobactam and ceftazidime/avibactam are commonly used in patients with MDR-Pseudomonas aeruginosa (PSA) pneumonia (PNA). This study compared outcomes between non-COVID-19 hospitalized patients with MDR-PSA PNA who received ceftolozane/tazobactam or ceftazidime/avibactam. METHODS: The study included non-COVID-19 adult hospitalized patients with MDR-PSA PNA in the PINC AI Healthcare Database (2016-22) who received ceftolozane/tazobactam or ceftazidime/avibactam within 3 days of index culture for ≥2 days. Outcomes were mortality, recurrent MDR-PSA PNA, discharge destination, post-index culture day length of stay (LOS) and costs (in US dollars, USD), and hospital readmission. RESULTS: The final sample included 197 patients (117 ceftolozane/tazobactam, 80 ceftazidime/avibactam). No significant differences were observed in mortality and post-index culture LOS and costs between groups. In the multivariable analyses, patients who received ceftolozane/tazobactam versus ceftazidime/avibactam had lower recurrent MDR-PSA PNA (7.9% versus 18.0%, P = 0.03) and 60 day PNA-related readmissions (11.1% versus 28.5%, P = 0.03) and were more likely to be discharged home (25.8% versus 9.8%, P = 0.03). Compared with ceftazidime/avibactam patients, ceftolozane/tazobactam patients had lower adjusted median total antibiotic costs (5052 USD versus 8099 USD, P = 0.003) and lower adjusted median comparator (ceftolozane/tazobactam or ceftazidime/avibactam) antibiotic costs (3938 USD versus 6441 USD, P = 0.005). In the desirability of outcome ranking (DOOR) analysis, a ceftolozane/tazobactam-treated patient was more likely to have a more favourable outcome than a ceftazidime/avibactam-treated patient [DOOR probability: 59.6% (95% CI: 52.5%-66.8%)]. CONCLUSIONS: Early treatment with ceftolozane/tazobactam may offer some clinical and cost benefits over ceftazidime/avibactam in patients with MDR-PSA PNA. Further large-scale studies are necessary to comprehensively understand the outcomes associated with these treatments for MDR-PSA PNA.
引用
- Lodise TP, Obi EN, Watanabe AH, et al. Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2024. PMID: 39258877. doi:10.1093/jac/dkae313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。